Teens with advanced-stage Hodgkin lymphoma survive longer without their disease getting worse when they receive the ...
Results of a multicenter retrospective cohort study evaluating the safety and efficacy of FTD/TPI plus ramucirumab in advanced gastric cancer (HGCSG2302). This is an ASCO Meeting Abstract from the ...
The FDA approved nivolumab and ipilimumab for unresectable or metastatic hepatocellular carcinoma, a prevalent and deadly liver cancer in the U.S. CHECKMATE-9DW trial results showed improved median ...
Reversing the standard approved dose levels of nivolumab (Opdivo) and ipilimumab (Yervoy) in metastatic melanoma led to less ...
Authors discuss the merits of using a pair of immunotherapy treatments aimed at separate targets. A study published this week in Nature Medicine demonstrated the feasibility of using 2 different ...
The US Food and Drug Administration (FDA) has expanded the approval of nivolumab (Opdivo, Bristol Myers Squibb) for the treatment of certain patients with resectable non–small cell lung cancer (NSCLC) ...
SAN FRANCISCO -- Post-surgical adjuvant nivolumab (Opdivo) improved survival outcomes in muscle-invasive bladder cancer (MIBC), regardless of the use of neoadjuvant chemotherapy, according to updated ...
Given over three- to five-minutes, Opdivo Qvantig demonstrated consistent efficacy and showed a comparable safety profile to intravenous Opdivo in the Phase 3 CheckMate-67T trial 1,3 Opdivo and Opdivo ...
The court directed Zydus to maintain detailed and audited records of its sales during this period so that the innovator can ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback